
DAVA Oncology
@DAVAOnc
DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
Dit vind je misschien leuk
@DAVAOnc Academia without friends at meetings is like Bermuda without sunshine Why would you want it? 🌞 Grateful for all I’ve learned from these friends. #DAVAGI




Day 3 of @DAVAOnc GI malignancies summit is in the books. Had to snap a pic with the maestro @vinaykjain17 who makes this and many other great events happen in the oncology space! #livertwitter

Nice to see friends, mentors and industry partners to embark on more trials in PDAC. @utswcancer
Can HDAC inhibitors expand treatment options in PDAC? Early data: ivaltinostat + chemo (ORR 25%, mOS 11.7 mo) and entinostat + IO (ORR 11%). Discussed by @Salthecancerguy @UTSW #DAVAGI




Delighted to be back in Bermuda 🏝️ for @DAVAOnc GI Malignancies Global Summit - sharing updates on new vaccine and immuno-oncology strategies for patients with colorectal and pancreatic cancer 🌍🎗️🧬


Excited to have these trials available for our patients! @AdventHealthCFL @drzakoncology
ACTION & RESTORE trials take exercise beyond survivorship, testing whether aerobic training during adjuvant therapy influences both clinical outcomes & biological remodeling in colon cancer. @Dr_M_Tejani @AdventHealthCFL #DAVAGI




Mayo Clinic, MD Anderson, Stanford and U Miami representing NETs at #DavaOnc Day 3 of 4 done!! @DAVAOnc

Ending @DAVAOnc GI malignancies on a high note with a session on liver metastases and locally advanced #HCC moderated by @docamitgs @sepideh_gholami #livertwitter

The very last @DAVAOnc summit on GI malignancies is underway. Congratulations to @vinaykjain17 and the DAVA team for another tour de force. Over 170 talks in 4 days. Lots of fruitful interactions and learning! #DAVAGI

The 2025 DAVA Bermuda GI Summit has successfully concluded. We deeply appreciate the contributions of all attendees for their expert knowledge, thoughtful discussions, and active participation. #DAVAGI




Gastric cancer with peritoneal metastases (20–45% cases; OS 3–4 mountreated) remains difficult to treat. @Jenny_J_Li @MDAndersonNews reviewed IP chemo approaches (HIPEC, NIPEC, PIPAC); early trials show promise but remain investigational. #DAVAGI




Starting Now: Peritoneal Mets and Appendiceal Cancer Moderated by: @vinaykjain17 #DAVAGI

EpCAM is overexpressed in GI cancers. Dr. Andrew Coveler @FredHutch highlighted KK-2269 & BA3182. KK-2269 (EpCAM–CD40) showed preclinical synergy w/ docetaxel; trials ongoing. BA3182 (EpCAM–CD3 CAB, n=39) showed manageable safety & favorable SC PK vs IV. #DAVAGI




Starting Now: Antibody-drug Conjugates Moderated by: @kanwal_raghav @MDAndersonnews #DAVAGI

CCNE1 amplification (~4–10% of esophagogastric cancers) is linked to CIN, poor prognosis & resistance. At #DAVAGI, @RyanMoyMDPhD @columbiacancer discussed PKMYT1 inhibition with lunresertib(RP-6306), showing preclinical activity & synergy with anti-PD1.




At #DAVAGI, @rutikamehtaMD presented utility of ctDNA MRD testing in gastric/upper GI cancers: persistence/rise predicts recurrence. ctDNA detects recurrence upto 3.5 mo before imaging. In surveillance, positivity→81% recurrence, mRFS 6 mo; negativity→13.5% recurrence, NR mRFS.



Starting Now: Emerging Approaches to Increase IO Efficacy in GE Junction Tumors Moderated by: Dr. Manish Shah @WeillCornell #DAVAGI

Cancer-driven vagal hyperactivation may contribute to cachexia. Dr. @drsmags (@MDAndersonNews) discusses vagal blockade, which reduced cachexia and improved survival in PDAC models. Trials are planned to test QOL outcomes. #DAVAGI



In Locally Advanced Pancreatic Cancer (LAPC), PANOVA-3 showed TTF + gem-nab-pacimproved mOS and pain-free survival, though PFS and ORR were similar. Dr. @MPishvaian (@hopkinskimmel) notes device was well tolerated; biomarker work ongoing. #DAVAGI



Zenocutuzumab is a bispecific antibody blocking HER2-HER3 heterodimerization in NRG1+ cancers. Dr. @DrGManji from @ColumbiaMed discussed its activity in pancreatic cancer and recent FDA approval for use in NRG1 fusion+ PDAC. #DAVAGI




Starting Now: Targeted Agents for Pancreatic Cancer Moderated by: Dr. Bach Arladan @umiamimedicine #DAVAGI

United States Trends
- 1. James Franklin 43.5K posts
- 2. Cowboys 45.4K posts
- 3. Drake Maye 14K posts
- 4. George Pickens 7,466 posts
- 5. Jets 104K posts
- 6. Penn State 59.7K posts
- 7. Steelers 49.7K posts
- 8. Rico Dowdle 3,704 posts
- 9. Diggs 7,360 posts
- 10. Colts 44.5K posts
- 11. Justin Fields 21.9K posts
- 12. Saints 52.6K posts
- 13. Cooper Rush 2,879 posts
- 14. #Browns 3,015 posts
- 15. Eberflus 2,251 posts
- 16. #RavensFlock 2,430 posts
- 17. Zay Flowers 1,939 posts
- 18. Huntley 2,916 posts
- 19. Puka 8,008 posts
- 20. Rodgers 7,547 posts
Dit vind je misschien leuk
-
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Krina Patel
@DrKrinaPatel -
drjoannarhodes
@drjoannarhodes1 -
SWOG Cancer Research Network
@SWOG -
Suresh S. Ramalingam, MD, FASCO
@RamalingamMD -
Eric J. Small, MD, FASCO
@ASCOPres -
Jason Westin, MD FACP FASCO
@Lymphoma_Doc -
iwCLL
@iwCLL -
Vishal Navani, MD
@navstruck -
Julie Vose
@DrJulieVose -
Tycel Phillips
@LymphClinician -
Ticiana Batista (Leal)
@LealTiciana -
Binay Shah, MD, MHA
@binayshah -
Danilov Lab
@DanilovLab -
Andrew M. Evens, DO, MBA, MSc
@DrAEvens
Something went wrong.
Something went wrong.